Syros Pharmaceuticals (SYRS)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	60.39 mm	60.39 mm	60.39 mm	60.39 mm	60.39 mm	60.39 mm
Cash burn (monthly)	6.90 mm	4.58 mm	8.73 mm	9.30 mm	6.90 mm	8.33 mm
Cash used (since last report)	60.91 mm	40.42 mm	77.09 mm	82.19 mm	60.91 mm	73.62 mm
Cash remaining	-518.68 k	19.98 mm	-16.69 mm	-21.79 mm	-518.68 k	-13.22 mm
Runway (months of cash)	-0.1	4.4	-1.9	-2.3	-0.1	-1.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

SYRS institutional ownership history Ownership history

41.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	8	73	-89.0%
Opened positions	0	15	EXIT
Closed positions	65	16	+306.3%
Increased positions	1	11	-90.9%
Reduced positions	4	15	-73.3%

13F shares	Current	Prev Q	Change
Total value	7.67 mm	39.82 bn	-100.0%
Total shares	11.24 mm	31.98 mm	-64.8%
Total puts	0.00	1.27 mm	EXIT
Total calls	0.00	208.81 k	EXIT
Total put/call ratio	–	6.1	–

Largest owners	Shares	Value	Change
Artal International S.C.A.	3.57 mm	$0.00	0.0%
Bain Capital Life Sciences Fund II	2.75 mm	$6.90 mm	0.0%
Avidity Partners Management	2.05 mm	$348.00 k	+92.7%
Invus Global Management	1.06 mm	$181.00 k	-70.9%
Samsara BioCapital	707.11 k	$148.00 k	-71.6%
Ally Bridge MedAlpha Master Fund	570.98 k	$0.00	0.0%
Adage Capital Partners GP, L.L.C.	531.91 k	$90.00 k	-74.3%
Point72 Asset Management	496.00	$0.00	-100.0%
Deep Track Capital	0.00	$0.00	EXIT

Largest transactions	Shares	Bought/sold	Change
Bain Capital Life Sciences Investors	0.00	-2.75 mm	EXIT
Invus Global Management	1.06 mm	-2.59 mm	-70.9%
Siren, L.L.C.	0.00	-2.59 mm	EXIT
Samsara BioCapital	707.11 k	-1.79 mm	-71.6%
Samsara BioCapital	0.00	-1.79 mm	EXIT
Adage Capital Partners GP, L.L.C.	531.91 k	-1.54 mm	-74.3%
Point72 Asset Management	496.00	-1.47 mm	-100.0%
Flagship Pioneering	0.00	-1.29 mm	EXIT
Avidity Partners Management	2.05 mm	+985.02 k	+92.7%
Vanguard	0.00	-953.31 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SYRS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Dec 24	Simonian Nancy A	Common Stock	Sell	Dispose S	No	No	0.2702	37,070	10.02 k	4,000
25 Nov 24	Simonian Nancy A	Common Stock	Sell	Dispose S	No	No	0.2653	134,713	35.74 k	41,070
19 Nov 24	Gerald E Quirk	Common Stock	Sell	Dispose S	No	No	0.2212	46,657	10.32 k	0
18 Nov 24	Jason Haas	Common Stock	Sell	Dispose S	No	No	0.2103	137,803	28.98 k	0
18 Nov 24	Kristin Stephens	Common Stock	Sell	Dispose S	No	No	0.22	36,133	7.95 k	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials

15 Apr 25

KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and